Cannell Capital buys $23.4 Million stake in BioTelemetry (BEAT)

BioTelemetry (BEAT) : Cannell Capital scooped up 77,425 additional shares in BioTelemetry during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 13, 2016. The investment management firm now holds a total of 1,557,748 shares of BioTelemetry which is valued at $23.4 Million.BioTelemetry makes up approximately 9.52% of Cannell Capital’s portfolio.

Other Hedge Funds, Including , Ajo Lp boosted its stake in BEAT in the latest quarter, The investment management firm added 4,190 additional shares and now holds a total of 25,144 shares of BioTelemetry which is valued at $376,909.Tfs Capital boosted its stake in BEAT in the latest quarter, The investment management firm added 115,555 additional shares and now holds a total of 132,510 shares of BioTelemetry which is valued at $2 Million. BioTelemetry makes up approx 0.29% of Tfs Capital’s portfolio. Alambic Investment Management added BEAT to its portfolio by purchasing 28,300 company shares during the most recent quarter which is valued at $427,613. BioTelemetry makes up approx 0.14% of Alambic Investment Management’s portfolio.Gabelli Funds boosted its stake in BEAT in the latest quarter, The investment management firm added 20,153 additional shares and now holds a total of 122,000 shares of BioTelemetry which is valued at $1.8 Million. BioTelemetry makes up approx 0.01% of Gabelli Funds’s portfolio.

BioTelemetry closed down -0.17 points or -0.99% at $17 with 5,56,521 shares getting traded on Wednesday. Post opening the session at $17.31, the shares hit an intraday low of $16.99 and an intraday high of $17.48 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

On the company’s financial health, BioTelemetry reported $0.20 EPS for the quarter, beating the analyst consensus estimate by $ 0.10 according to the earnings call on Apr 26, 2016. Analyst had a consensus of $0.10. The company had revenue of $48.60 million for the quarter, compared to analysts expectations of $46.54 million. The company’s revenue was up 12.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.06 EPS.

Leave a Reply

BioTelemetry - Is it time to Sell?

Top Brokerage Firms are advising their investors on BioTelemetry. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.